Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy

Inclusion Criteria: * The patient or a legally authorized representative must provide study-specific informed consent prior to study entry, had good compliance and cooperated with the follow-up. * Age at least 18 years * Pathologically (histologically or cytologically) proven diagnosis of limited stage small cell lung cancer (Stage Tx, T1-T4, N0-3, M0, American Joint Committee on Cancer \[AJCC\] staging, 8th edition \[Ed.\]), within 60 days prior to registration * Patients must have had measurable disease (per Response Evaluation Criteria in Solid Tumors \[RECIST\], version 1.1) prior to the required cycle of cCRT * Patients must be free of disease progression and not be able to receive other antitumor therapy within 6 weeks of completion of cCRT * Patients must submit archived or freshly biopsied tumor tissue (formalin-fixed, paraffin-embedded tissue block or approximately 15 unstained sections \[must have \>8 sections\]) along with the relevant pathology report. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 30 days prior to registration * Patient life expectancy must be \>12 weeks Exclusion Criteria: * Mixed SCLC or NSCLC confirmed by histology * Previous tumor resection for LS-SCLC * Any patient treatable by surgery or stereotactic body radiation therapy/stereotactic ablative radiation therapy should be excluded * Expected to receive any other form of anti-tumor therapy during the study period * Previous treatment with PARP inhibitor drugs…